ERAD Therapeutics Inc. is currently developing our proprietary CTB Delivery System to deliver therapeutic molecules to every cell in the human body, including neuronal cells across the Blood-Brain-Barrier (BBB.) We exploit our proprietary CTB Delivery System in two ways:
1/ Protein Replacement Therapy: To deliver therapeutic proteins to all cells throughout the body, including crossing the Blood-Brain-Barrier to brain/neuronal cells. Our current focus is on Enzyme Replacement Therapy for Gaucher Disease where we are utilizing our proprietary CTB Delivery System to deliver glucocerebrosidase to patients with Gaucher Disease. In doing so, ERAD Therapeutics Inc. delivers a significant improvement to existing ERT markets by delivering replacement enzymes to neuronal cells tissues not ordinarily accessible by current ERT methods. We are investigating the delivery of other types of therapeutic proteins via our CTB Delivery System to treat other Orphan Diseases.
2/ ERAD Blockade: To deliver a modified version of the CT A (mCT) sub-unit in order to temporarily block the ERAD process and allow the mis-folded but functional protein to be rescued and delivered to its site of action in the cell. An example of this is the rescue of the del508CFTR protein in Cystic Fibrosis to restore normal chloride transport function in these cells. We will use our proprietary CTB Delivery System to deliver the mCT molecules to every cell in the body.